Global Veterinary Clostridium Vaccine Market 2017-2021
About Veterinary Clostridium Vaccine
Clostridium bacteria are widely found in soil and the guts of various animals. These microbes are anaerobic in nature and produce a wide range of toxins leading to various diseases in animals. Some of these diseases are zoonotic in nature. Vaccines play a major role in protecting the animals against all the Clostridia diseases. Various types of vaccines are available, either in a single form or in combinations, which consist of bacterins, toxoids, or mixtures of bacterins and toxoids.
Technavio’s analysts forecast the global veterinary clostridium vaccine market to grow at a CAGR of 4.96% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global veterinary clostridium vaccine market for 2017-2021. To calculate the market size, the report considers sales of Clostridium vaccines.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Veterinary Clostridium Vaccine Market 2017-2021
Technavio recognizes the following companies as the key players in the global veterinary clostridium vaccine market: Elanco, Merck, Merial (now part of Boehringer Ingelheim), and Zoetis.
Other Prominent Vendors in the market are: Advaxis, AMPLIPHI, Aratana Therapeutics, ARKO Labs, Bayer, CanFel Therapeutics, Ceva, Colorado Serum Company, Epitopix, Genus, Hygieia Biological Laboratories, NEXVET, Nuovo Biologics, Valneva SE, Vetoquinol, and Virbac.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is inorganic growth strategies. The veterinary Clostridium vaccine market has been witnessing an increasing trend in strategic alliances and acquisitions among vendors. The vendors are planning for inorganic growth strategies such as acquisitions and partnerships to boost the research and to improve its penetration in emerging markets.”
According to the report, one driver in the market is advances in technology. The advances in technology have improved the overall pharmacokinetics and dynamics of vaccines along with cost-effective processes. The use of cell line culture in manufacturing viral vaccinations has been increased, which improved the quality of vaccinations. For instance, Valneva SE developed EB66 cell line, which can be used for high-efficiency vaccine production. This cell line is derived from stem cells of duck embryo. This can be used for large-scale manufacturing of veterinary vaccines.
Further, the report states that one challenge in the market is manufacturing and storage issues. A vaccine involves a complex network of processes ranging from manufacturing to delivery. The cost-intensive manufacturing issues associated with vaccines get quadrupled with strict regulatory laws. The protocol set by the FAO for manufacturing animal vaccines has rigorous processes like master seed and master stock analysis. These processes are crucial to producing quality vaccines, as they involve analysis of microbes, which are used in vaccine manufacturing followed by sterilization process and storage process.
Elanco, Merck, Merial (now part of Boehringer Ingelheim), Zoetis, Advaxis, AMPLIPHI, Aratana Therapeutics, ARKO Labs, Bayer, CanFel Therapeutics, Ceva, Colorado Serum Company, Epitopix, Genus, Hygieia Biological Laboratories, NEXVET, Nuovo Biologics, Valneva SE, Vetoquinol, and Virbac.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook